Barclays raised the firm’s price target on Ligand (LGND) to $150 from $125 and keeps an Overweight rating on the shares ...

In a report released yesterday, Douglas Miehm from RBC Capital maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality. On average, it took eight days ...

HC Wainwright restated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) in a report published ...

Ligand Pharmaceuticals Inc (LGND) reports a 58% revenue increase and raises 2024 guidance, showcasing strong business ...

Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market ...

Ligand Pharmaceuticals Inc ( (LGND) ) has released its Q3 earnings. Here is a breakdown of the information Ligand Pharmaceuticals Inc presented ...

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the company, Marketbeat.com ...

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 75 cents per share. The drugmaker posted revenue of ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m.

Ligand Pharmaceuticals Inc. (LGND)股价已达到重要里程碑，创下52周新高116.25美元。这一峰值反映了该公司股票过去一年令人印象深刻的113.73%的同比增长。投资者对Ligand的商业模式和未来前景表现出更大的信心，推动了股票的强劲表现，使其目前处于52周区间的顶端。股价飙升至这一新高点凸显了市场对Ligand战略举措的积极反应及其持续增长潜力的认可。 在其他近 ...